We give you a written timeline estimate for your case before you commit.Get my quote
Isembyld (apitegromab-mstn): what it is and how families in the Gulf can get it
Plain facts from FDA and manufacturer sources, and the legal routes for families in the Gulf.
Reviewed by the Reserve Meds clinical operations team on 13 October 2026.
The short answer
Isembyld (apitegromab-mstn) is an FDA-approved muscle-targeted antibody given as an add-on to SMN2-targeted treatment made by Scholar Rock. The FDA approved it on 11 September 2026 for spinal muscular atrophy (SMA), as an add-on. At approval, a European application was still pending. We found no Gulf registration in public sources as of 13 October 2026. In Saudi Arabia, the UAE, Kuwait and Qatar, the legal route is usually a named-patient request: the treating hospital asks the national regulator for permission to import it for one patient. We give you a written timeline estimate for your case before you commit.
About Isembyld
- Generic name: apitegromab-mstn
- Made by: Scholar Rock
- US FDA approval: 11 September 2026
- Approved for: spinal muscular atrophy (SMA) in adults and children 2 years of age and older who are currently receiving a survival motor neuron 2 (SMN2)-targeted treatment
- How it is given: an intravenous (IV) infusion, 10 mg/kg, once every 4 weeks
Approval was based on the phase 3 SAPPHIRE trial. Isembyld is used together with existing SMA treatments, not instead of them. Your neurologist will explain the expected benefit and the monitoring plan.
Country guides
- Isembyld in Saudi Arabia
- Isembyld in the UAE
- Isembyld in Kuwait
- Isembyld in Qatar
- Isembyld in Bahrain
How Reserve Meds helps
Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We coordinate access to FDA-approved medicines only. We help your doctor and hospital prepare the request, arrange US supply and shipping once approval is in place, and keep your family updated. We do not prescribe or give medical advice. Your coordination fee is quoted in writing for your case before you commit. No hidden charges.
Ask about Isembyld
Tell us the medicine and your country. We reply within one business day. On WhatsApp we usually reply the same day.
Frequently asked questions
What is Isembyld?
Isembyld (apitegromab-mstn) is a muscle-targeted antibody given as an add-on to SMN2-targeted treatment made by Scholar Rock. The US FDA approved it on 11 September 2026 for spinal muscular atrophy (SMA) in adults and children 2 years of age and older who are currently receiving a survival motor neuron 2 (SMN2)-targeted treatment.
Is Isembyld approved outside the United States?
At approval, a European application was still pending. We found no registration in Saudi Arabia, the UAE, Kuwait or Qatar in public sources as of 13 October 2026. A hospital pharmacy should confirm with the national regulator.
Can families in the Gulf get Isembyld?
Yes, usually through a named-patient request. The treating hospital asks the national regulator, such as SFDA in Saudi Arabia, for permission to import it for one patient.
How much does Isembyld cost?
Medicine price: quote on request. Your total cost is quoted in writing for your case before you commit. No hidden charges.
What does Reserve Meds do?
Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We coordinate the paperwork, supply and shipping with your doctor and hospital. We do not prescribe or give medical advice.
Sources
Checked on 13 October 2026. Regulator rules change. Your hospital pharmacy confirms the current procedure before filing.
- Drugs.com: Isembyld FDA approval history (approved 11 Sep 2026; SAPPHIRE trial)
- BioPharma Dive: Scholar Rock SMA drug Isembyld wins FDA approval
- Cure SMA: FDA approves ISEMBYLD for people living with SMA (10 mg/kg IV every 4 weeks)
- PharmaKnowl: Named Patient Program in Saudi Arabia (reference regulators, hospital and importer declarations, patient consent)
- Baker McKenzie: new Emirates Drug Corporation replaces MOHAP as federal regulator of medical products (Federal Decree No. 28 of 2023)
- Al Tamimi & Co: Kuwait Ministry of Health restrictions on the supply of non-registered medical products (Resolution No. 100 of 2023)
- Qatar Ministry of Public Health: services for companies (pharmacy and drug control)
Related
Clinical trials and expanded access
On 17 October 2026 we searched ClinicalTrials.gov, the clinical study registry of the US National Library of Medicine, for studies that list apitegromab as an intervention. The search found studies that are recruiting or not yet recruiting. See the current list on ClinicalTrials.gov.
Whether a patient can join a trial or an expanded access program is decided by the study team or the manufacturer, together with the treating doctor. Reserve Meds does not run trials or supply investigational medicines. We can help you and your doctor read a listing and understand the route.